Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 397-406

  Ko, Jen Chung ^a,b,c   Chiu, Hsien Chun ^d   Wo, Ting Yu ^d   Huang, Yi Jhen ^d   Tseng, Sheng Chieh ^d   Huang, Yu Ching ^d   Chen, Huang Jen ^d   Syu, Jhan Jhang ^d   Chen, Chien Yu ^d   Jian, Yun Ting ^d   Jian, Yi Jun ^d   Lin, Yun Wei ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b YUANPEI UNIVERSITY   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Cytotoxicity; Gefitinib; Metformin; MSH2; Non small cell lung cancer; P38 MAPK; Tyrosine kinase inhibitor

Indexed keywords

GEFITINIB; MESSENGER RNA; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN MSH2; SMALL INTERFERING RNA; TRYPAN BLUE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RISK; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; TRANSIENT EXPRESSION; WESTERN BLOTTING;

CYTOTOXICITY; GEFITINIB; METFORMIN; MSH2; NON-SMALL CELL LUNG CANCER; P38 MAPK; TYROSINE KINASE INHIBITOR;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MAP KINASE KINASE 3; MAP KINASE KINASE 6; METFORMIN; MUTATION; MUTS HOMOLOG 2 PROTEIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; QUINAZOLINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSGENES;

EID: 84887617406     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.09.011     Document Type: Article

References (52)

1. Silvestri G.A., Spiro S.G. Carcinoma of the bronchus 60 years later. Thorax 2006, 61:1023-1028.
2. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 1999, 49:8-31.
3. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
4. Veale D., Kerr N., Gibson G.J., Kelly P.J., Harris A.L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993, 68:162-165.
5. Cerny T., Barnes D.M., Hasleton P., Barber P.V., Healy K., Gullick W., et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer 1986, 54:265-269.
6. Arteaga C.L. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 2003, 21:289s-291s.
7. Raymond E., Faivre S., Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000, 60(Suppl. 1):15-23. discussion 41-2.
8. Brehmer D., Greff Z., Godl K., Blencke S., Kurtenbach A., Weber M., et al. Cellular targets of gefitinib. Cancer Res 2005, 65:379-382.
9. Baselga J., Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000, 60(Suppl. 1):33-40. discussion 41-2.
10. Normanno N., Maiello M.R., De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action. J Cell Physiol 2003, 194:13-19.
11. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8:3-9.
12. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000, 6:4885-4892.
13. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053-2063.
14. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004, 3:465-472.
15. Lu P.H., Kuo T.C., Chang K.C., Chang C.H., Chu C.Y. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. Br J Dermatol 2011, 164:38-46.
16. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006, 7:335-346.
17. Li G.M. Mechanisms and functions of DNA mismatch repair. Cell Res 2008, 18:85-98.
18. Jun S.H., Kim T.G., Ban C. DNA mismatch repair system. Classical and fresh roles. FEBS J 2006, 273:1609-1619.
19. Genschel J., Littman S.J., Drummond J.T., Modrich P. Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. J Biol Chem 1998, 273:19895-19901.
20. Castrilli G., Fabiano A., La Torre G., Marigo L., Piantelli C., Perfetti G., et al. Expression of hMSH2 and hMLH1 proteins of the human DNA mismatch repair system in salivary gland tumors. J Oral Pathol Med 2002, 31:234-238.
21. Hamid A.A., Mandai M., Konishi I., Nanbu K., Tsuruta Y., Kusakari T., et al. Cyclical change of hMSH2 protein expression in normal endometrium during the menstrual cycle and its overexpression in endometrial hyperplasia and sporadic endometrial carcinoma. Cancer 2002, 94:997-1005.
22. Hussein M.R., El-Ghorori R.M., El-Rahman Y.G. Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas. Int J Exp Pathol 2006, 87:297-306.
23. Hussein M.R., Sun M., Roggero E., Sudilovsky E.C., Tuthill R.J., Wood G.S., et al. Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog 2002, 34:35-44.
24. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann Intern Med 2002, 137:25-33.
25. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
26. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., Evans J.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32:1620-1625.
27. Tomic T., Botton T., Cerezo M., Robert G., Luciano F., Puissant A., et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011, 2:e199.
28. Taubes G. Cancer research. Cancer prevention with a diabetes pill?. Science 2012, 335:29.
29. Tsai M.S., Weng S.H., Chen H.J., Chiu Y.F., Huang Y.C., Tseng S.C., et al. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide. Mol Cancer Ther 2012, 11:561-571.
30. Koshiji M., To K.K., Hammer S., Kumamoto K., Harris A.L., Modrich P., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005, 17:793-803.
31. Remsing L.L., Bahadori H.R., Carbone G.M., McGuffie E.M., Catapano C.V., Rohr J. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target. Biochemistry 2003, 42:8313-8324.
32. Chatterjee S., Zaman K., Ryu H., Conforto A., Ratan R.R. Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol 2001, 49:345-354.
33. Jia Z., Zhang J., Wei D., Wang L., Yuan P., Le X., et al. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res 2007, 67:4878-4885.
34. Bailey C.J., Turner R.C. Metformin. N Engl J Med 1996, 334:574-579.
35. Chaudhary S.C., Kurundkar D., Elmets C.A., Kopelovich L., Athar M. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol 2012, 88:1149-1156.
36. Kolodner R. Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 1996, 10:1433-1442.
37. Modrich P., Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 1996, 65:101-133.
38. Mo C., Dai Y., Kang N., Cui L., He W. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. J Biol Chem 2012, 287:19242-19254.
39. Warnick C.T., Dabbas B., Ford C.D., Strait K.A. Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells. J Biol Chem 2001, 276:27363-27370.
40. Scherer S.J., Welter C., Zang K.D., Dooley S. Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem Biophys Res Commun 1996, 221:722-728.
41. Menssen A., Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A 2002, 99:6274-6279.
42. Gonzalez-Angulo A.M., Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010, 16:1695-1700.
43. Alimova I.N., Liu B., Fan Z., Edgerton S.M., Dillon T., Lind S.E., et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8:909-915.
44. Ben Sahra I., Laurent K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27:3576-3586.
45. Gotlieb W.H., Saumet J., Beauchamp M.C., Gu J., Lau S., Pollak M.N., et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008, 110:246-250.
46. Wang L.W., Li Z.S., Zou D.W., Jin Z.D., Gao J., Xu G.M. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008, 14:7192-7198.
47. Wu N., Gu C., Gu H., Hu H., Han Y., Li Q. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 2011, 58:482-490.
48. Cuenda A. Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007, 1773:1358-1375.
49. Ferrari G., Terushkin V., Wolff M.J., Zhang X., Valacca C., Poggio P., et al. TGF-beta1 induces endothelial cell apoptosis by shifting VEGF activation of p38(MAPK) from the prosurvival p38beta to proapoptotic p38alpha. Mol Cancer Res 2012, 10:605-614.
50. Morgillo F., Sasso F.C., Della Corte C.M., Vitagliano D., D'Aiuto E., Troiani T., et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res 2013, 19:3508-3519.
51. Shackelford D.B., Abt E., Gerken L., Vasquez D.S., Seki A., Leblanc M., et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013, 23:143-158.
52. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.